About Antidote
Antidote is a company based in London (United Kingdom) founded in 2008 by Jessica Mann. Antidote has raised $52 million across 5 funding rounds from investors including LBO France, Merck Global Health Innovation Fund and Smedvig Capital. The company has 39 employees as of December 31, 2023. Antidote offers products and services including Smart Match Search Engine and Precision Recruitment Services. Antidote operates in a competitive market with competitors including Evidation, myTomorrows, Dyania Health, SubjectWell and Clara Health, among others.
- Headquarter London, United Kingdom
- Employees 39 as on 31 Dec, 2023
- Founders Jessica Mann
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Antidote Technologies Ltd.
- Date of Incorporation 20 Apr, 2011
- Jurisdiction LONDON, ENGLAND
-
Annual Revenue
$10.68 M (USD)160as on Dec 31, 2021
-
Net Profit
Not available
-
EBITDA
-$2.08 M (USD)61as on Dec 31, 2021
-
Total Equity Funding
$52 M (USD)
in 5 rounds
-
Latest Funding Round
$23.2 M (USD), Series C
Jun 03, 2021
-
Investors
LBO France
& 5 more
-
Employee Count
39
as on Dec 31, 2023
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Antidote
Antidote offers a comprehensive portfolio of products and services, including Smart Match Search Engine and Precision Recruitment Services.
Tool that helps patients find appropriate clinical trials quickly.
Services for sponsors to fill clinical trials faster and efficiently.
People of Antidote
Unlock access to complete
Funding Insights of Antidote
Antidote has successfully raised a total of $52M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $23.2 million completed in June 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Antidote
Antidote has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include LBO France, Merck Global Health Innovation Fund and Smedvig Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investments are made in France and the US.
|
Locked | Locked | Locked | |
|
Corporate-backed venture capital is focused on the life science sector.
|
Locked | Locked | Locked | |
|
Investment in private equity and venture capital since 1996.
|
Locked | Locked | Locked |
Investor details for Antidote
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Antidote
Investment portfolio details for Antidote
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Antidote
Detailed financials for Antidote
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Antidote Comparisons
Peer comparison for Antidote
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Antidote
Antidote operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Evidation, myTomorrows, Dyania Health, SubjectWell and Clara Health, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Real-world health data is provided for research and decisions.
|
|
| Locked | Locked | Locked |
Platform provides access to drugs in development to patients and physicians
|
|
| Locked | Locked | Locked |
Patients for clinical trials are identified through a dedicated platform.
|
|
| Locked | Locked | Locked |
Clinical trials marketplace for patient recruitment solutions is provided.
|
|
| Locked | Locked | Locked |
Clinical trials are matched to patients via an online platform.
|
Detailed competitors of Antidote
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Antidote
Complete news archive for Antidote
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Antidote
Antidote was founded in 2008 and raised its 1st funding round 3 years after it was founded.
Antidote is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
Nicole Anuszkiewicz Batiste is the current CEO of Antidote.
Antidote is a funded company, having raised a total of $52M across 5 funding rounds to date.
As of Dec 31, 2023, the latest employee count at Antidote is 39.
Annual revenue of Antidote is $10.68M as on Dec 31, 2021.
Antidote, earlier known as TrialReach, is a metasearch engine, helps patients to find and compare treatments in development and to connect them directly with the doctorsinvestigators carrying out the research. It also allows healthcare providers to put their patient data in their EMR into TrialReachs platform at scale, enabling groups of patients to be automatically matched to potentially suitable clinical trials.TrialReach is already working with leading health organizations, including the World Health Organization, and claims that three-quarters of the top twenty pharmaceutical companies are using its platform to support their clinical trials.
Antidote's top competitors include Evidation, myTomorrows and Dyania Health.
Antidote offers Smart Match Search Engine and Precision Recruitment Services.
Antidote has 6 investors. Key investors include LBO France, Merck Global Health Innovation Fund, Smedvig Capital, Octopus Ventures, and Amadeus Capital Partners.